Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 6Unknown 2Terminated 2Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 15Lymphoid 3Genitourinary 3Thoracic 2Sarcoma 2Plasma cell 2Other hematologic neoplasm 2CNS 2Tumor-Agnostic 1Myeloid 1Gastrointestinal 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × palbociclib × Thoracic × Clear all
NCT03386929 2023-12-18

SPRING

Worldwide Innovative Network Association

Phase 1/2 Terminated
15 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02349633 2021-06-10

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Pfizer

Phase 1/2 Terminated
65 enrolled 61 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡